Skip to main content

Table 5 Adjusted Odds Ratio for high adherence to index OAC and to any OAC during 3, 6, 9 and 12 months of follow up

From: Real-world adherence for direct oral anticoagulants in a newly diagnosed atrial fibrillation cohort: does the dosing interval matter?

 

3 months

6 months

9 months

12 months

Adj OR

95% CI

Adj OR

95% CI

Adj OR

95% CI

Adj OR

95% CI

PDC ≥ 0.80 to index OAC

 R vs. D

1.34

1.27–1.40*

1.32

1.25–1.39*

1.37

1.30–1.44*

1.40

1.32–1.48*

 A vs. D

1.41

1.33–1.50*

1.52

1.42–1.62*

1.67

1.56–1.79*

1.73

1.60–1.88*

 A vs. R

1.06

0.99–1.12

1.15

1.08–1.23*

1.22

1.14–1.31*

1.24

1.14–1.34*

PDC ≥ 0.80 to any OAC

 R vs. D

1.26

1.20–1.33*

1.23

1.17–1.29*

1.29

1.23–1.36*

1.32

1.25–1.40*

 A vs. D

1.28

1.20–1.36*

1.40

1.31–1.49*

1.55

1.44–1.66*

1.62

1.50–1.76*

 A vs. R

1.01

0.95–1.08

1.13

1.06–1.21*

1.20

1.12–1.29*

1.23

1.13–1.34*

  1. DOAC direct-acting oral anticoagulant, OAC oral anticoagulant, R rivaroxaban, D dabigatran, A apixaban, OR odds ratio, CI confidence interval, PDC proportion of days covered
  2. *denotes statistical significance at P <0.05